GlassScriptPhysician profile
Jeffrey C Marc
NPI 1962578229
$2,828.79
in general payments reported to CMS, 2019-2025
21 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $421 · 2021: $388 · 2022: $333 · 2023: $270 · 2024: $323 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $415.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $330.18 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $316.37 | 2020-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $311.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $301.83 | 2019-2024 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $215.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.87 | 2022-2025 | Jardiance |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $116.75 | 2019 | |
| Amarin Pharma, INC. | $114.65 | 2019-2021 | |
| Lilly USA, LLC | $104.00 | 2022-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $48.16 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $42.44 | 2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $37.96 | 2021 | |
| Phathom Pharmaceuticals, INC. | $32.73 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.44 | 2019 | |
| Allergan, INC. | $18.00 | 2020 | |
| Astellas Pharma US INC | $15.65 | 2019 | |
| Sanofi Pasteur INC. | $15.01 | 2019 | |
| Vistapharm, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Marc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.